| Role of aldosterone in congestive heart failure. | |
| | |
MedLine Citation:
|
PMID: 8460078 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Antialdosterone therapy in patients with secondary hyperaldosteronism due to myocardial failure must accomplish the following: (1) reduce or preferably normalize plasma aldosterone levels by blockade of excessive synthesis, (2) antagonize the renal and systemic effects of aldosterone at its receptor sites, and (3) minimize the presence of multiple stimuli to aldosterone secretion. Fulfillment of these goals likely requires the blockade of angiotensin II-induced aldosterone secretion (ie, angiotensin-converting enzyme inhibition) with an antagonist of aldosterone receptors (ie, spironolactone [Aldactone]). Despite the potential for hyperkalemia with this combined use of medications, particularly in patients with impaired renal function, such therapy is likely to attenuate the salt-acquisitive state that is characteristic of myocardial failure. |
| | |
Authors:
|
K T Weber; D Villarreal |
Related Documents
:
|
2184198 - Drug therapy of heart failure. 18377538 - Rhythm management in pediatric heart failure. 1380618 - Left ventricular remodeling after myocardial infarction: does the cardiac renin-angiote... 20932268 - Homocysteine, cardiovascular inflammation, and myocardial remodeling. 11401108 - A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in car... 12154418 - Cardiac marker responses to coronary artery bypass graft surgery with cardiopulmonary b... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: Postgraduate medicine Volume: 93 ISSN: 0032-5481 ISO Abbreviation: Postgrad Med Publication Date: 1993 Apr |
Date Detail:
|
Created Date: 1993-04-27 Completed Date: 1993-04-27 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0401147 Medline TA: Postgrad Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 203-7, 211-2, 216-8 passim Citation Subset: AIM; IM |
Affiliation:
|
University of Missouri-Columbia School of Medicine 65212. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
metabolism*,
secretion Atrial Natriuretic Factor / metabolism Heart Failure / drug therapy, physiopathology* Humans Renin-Angiotensin System Spironolactone / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
R01-HL-31701/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
52-01-7/Spironolactone; 52-39-1/Aldosterone; 85637-73-6/Atrial Natriuretic Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hematologic emergencies. Management of hyperleukocytic syndrome, DIC, and thrombotic thrombocytopeni...
Next Document: Topical corticosteroid 'addiction'. A cause of perioral dermatitis.